Trial Profile
A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Aug 2022
Price :
$35
*
At a glance
- Drugs Letaplimab (Primary) ; Rituximab (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Innovent Biologics
- 29 Mar 2022 Status changed from active, no longer recruiting to completed.
- 20 Jul 2021 Planned number of patients changed from 92 to 49.
- 20 Jul 2021 Planned End Date changed from 31 Jan 2022 to 12 Nov 2021.